Key Points

• 9.0 million HIV serology tests were performed in 2025 by clinical laboratories, an increase of 7% compared to 2024. Of these tests, 2.3 million (25%) were performed without a prescription and without any upfront costs (the “Mon test IST” program).
• Approximately 4,983 people learned they were HIV-positive in 2025, a significant decrease since 2023 (5,318 new diagnoses).
• More than half (54%) of those who learned they were HIV-positive in 2025 were born abroad.
• The most common modes of transmission among people diagnosed in 2025 were heterosexual intercourse (53%) and sex between men (42%).Transgender individuals infected through sexual contact accounted for 2% of new diagnoses, people who inject drugs for 1%, and mother-to-child transmission for 1%.
• The number of new cases among MSM has remained stable since 2022, regardless of whether they were born in France or abroad.
• The epidemic continues to be marked by a concerning situation in French Guiana, Mayotte, the French West Indies, and the Île-de-France region.
• 39% of HIV infections were diagnosed at a late stage in 2025.
• The number of new infections in France was estimated at 3,464 in 2025. In 2024 in France, 95% of people living with HIV had been diagnosed; of these, 97% were receiving antiretroviral therapy; and of those, 97% had an undetectable viral load (< 200 copies/ml).
• The incidence of HIV infection in France has remained stable since 2023 despite progress made in prevention (e.g., improved screening) and favorable estimates regarding the care continuum. The number of undiagnosed people living with HIV in France was estimated at 8,463 in 2025. This underscores the need to continue efforts to better tailor combined prevention measures to the needs of specific populations and regions—particularly those most at risk—in order to achieve the goal of eliminating HIV infection.